These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Response to ‘Onabotulinum toxin injection in neurogenic detrusor overactivity: intradetrusor versus suburothelial’. Krhut J; Samal V; Nemec D; Zvara P Spinal Cord; 2013 Sep; 51(9):726. PubMed ID: 23797569 [No Abstract] [Full Text] [Related]
10. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study. Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679 [TBL] [Abstract][Full Text] [Related]
11. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973 [TBL] [Abstract][Full Text] [Related]
12. Effect of Botulinum Toxin A on Bladder Pain-Molecular Evidence and Animal Studies. Yeh TC; Chen PC; Su YR; Kuo HC Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32028597 [TBL] [Abstract][Full Text] [Related]
14. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder. Ellsworth P; Travis M Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617 [TBL] [Abstract][Full Text] [Related]
15. Electromotive drug administration of lidocaine to anesthetize the bladder before botulinum-A toxin injections into the detrusor. Schurch B; Reitz A; Tenti G Spinal Cord; 2004 Jun; 42(6):338-41. PubMed ID: 15007374 [TBL] [Abstract][Full Text] [Related]
16. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Krhut J; Samal V; Nemec D; Zvara P Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191 [TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554 [TBL] [Abstract][Full Text] [Related]
18. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. Harris MA; Harding C; Fulford S; Whiteway J BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980 [No Abstract] [Full Text] [Related]
19. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295 [TBL] [Abstract][Full Text] [Related]
20. Submucosal injections of botulinum toxin A in women with refractory idiopathic detrusor overactivity. Onyeka BA; Shetty A; Ilangovan K; Saxena A Int J Gynaecol Obstet; 2010 Jul; 110(1):68-9. PubMed ID: 20347085 [No Abstract] [Full Text] [Related] [Next] [New Search]